Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer

NCT00408694 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00408694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2006
Completion date
December 15, 2011
Enrollment
46 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii nasopharyngeal keratinizing squamous cell carcinoma ajcc v7, stage iii nasopharyngeal keratinizing squamous cell carcinoma ajcc v7, stage iii nasopharyngeal undifferentiated carcinoma ajcc v7, stage iv nasopharyngeal keratinizing squamous cell carcinoma ajcc v7, stage iv nasopharyngeal undifferentiated carcinoma ajcc v7